For internal irradiation in molecular radiotherapy the time-course of the induction and the number of RIF are different from those following external irradiation, since after radionuclide administration cells are irradiated not only for seconds or minutes, but are continuously irradiated over a longer period of time with a permanently changing dose rate [ 29].
Dose influences mechanism; and over a wide range of doses, one can envision that mechanism will change with changing dose.
In addition, in silico models are incorporating this information with cell cell and tissue level behavior to predict outcomes of changing dose and time within a developing organ, without the need to pick up a pipet.
In our analysis, the ETA assumption may have been partially violated in that some dose profiles (e.g. abruptly changing dose from 5 to 20 mg) would not be attainable in a flexible dose trial where protocols allow only one increment increase at a time.
Data collected on treatment modalities included dose, prescription date and reason for changing dose and/or therapy.
The model can be used to quantify the conditions of changing dose schedules that would be optimal for any vaccine.
Generalized but non-specific dose adjustment methods including changing dose amount or frequency, utilization of extended or continuous infusion have been used in most units practising TDM routinely [ 22].
Underuse can be sporadic or systematic, from forgetting an occasional dose to changing dosing schedules; patients with underuse are at a higher risk for adherence-related morbidity [ 7].
27 It is very important that a plan is agreed on how to monitor the effects of starting, stopping and changing doses (ie, agree on a scheme of monitoring-specific parameters and responsibilities for the monitoring).
Our approach incorporates changing dosing requirements as children grow, and accounts for a range of scenarios for the availability of pediatric ARV formulations in different countries and settings.
Numerous products are needed in varying strengths to accommodate changing doses as children grow, which fragments the pediatric market for a given ARV into even smaller niches.
